Medifast, Inc.
NYSE:MEDPersonal Products & Services
Consumer Cyclical
$12.20 -0.04%
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
52W Low $9.22High $15.46
Volume 0.09M
Average 0.21M
Income Statement
Follow revenue through to earnings.
Revenue
$385.79M
FY 2025 · Annual
-36.0% YoYOperating Income
-$14.21M
FY 2025 · Annual
Net Income
-$18.67M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| 11.71M | 11.2M | 10.88M | 10.93M | 10.98M | |
| 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
MED Earnings Waterfall · TTM
NYSE:MED · Revenue to Net Income
Key Ratios
EPS$-1.83
Gross Margin69.9%
Net Margin-6.8%
P/E Ratio-4.0
P/S Ratio1.5
Analysis
$346.1M of revenue converted into -$20.0M of net income for the selected period. Gross margin is 69.9% and net margin is -6.8%, showing how much revenue survives after costs and taxes. EPS is $-1.83, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 10-Q | Quarterly report | Oct 26, 2026 | |
| 8-K | Current report | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 30, 2026 |
How much revenue does MED generate?
Medifast, Inc. (MED) reported $385.79M of revenue in fiscal 2025.
Is MED profitable?
Medifast, Inc. (MED) reported -$18.67M of net income, with a net margin of -4.8%.
Continue the stock analysis
Jump to another research area for this company.